文献速递神经肿瘤

临床与病理特征可预测垂体腺瘤术后复发与进展:一项随访10年的回顾性研究

Clinical and Pathologic Characteristics Predicted the Postoperative Recurrence and Progression of Pituitary Adenoma: A Retrospective Study with 10 Years Follow-Up.
PubMed 文献 · World Neurosurg · 2018-07-04

该研究回顾性分析2008—2016年在四川大学华西医院接受手术的垂体腺瘤患者,中位随访44.0个月,肿瘤复发48例(25.0%)、残余进展29例(37.2%);增殖潜能、侵袭性、较大肿瘤体积、高危垂体腺瘤亚型及术后残余为术后早期复发/进展的危险因素,并据此提出新的临床病理分级用于预后预测。

要点

  • 中位随访44.0个月,肿瘤复发48例(25.0%),残余进展29例(37.2%)。
  • 增殖潜能(HR 2.188)、侵袭性(HR 1.698)、较大肿瘤体积(HR 1.029)、高危亚型(HR 2.151)、术后残余(HR 1.941)为早期复发/进展危险因素。
  • 与1a级相比,1b、2a、2b级肿瘤复发/进展概率分别增加5.133倍、4.467倍、20.1倍。

核心结论

  • 作者提出的垂体腺瘤临床病理分级在预测预后方面显示出显著价值,并成功识别出复发或残余再生长等临床侵袭性更强的病例。
  • 作者认为该预后分级可能有助于识别侵袭性垂体腺瘤并为患者决定合适的治疗策略。

研究设计与样本

  • 研究为回顾性研究,纳入2008—2016年在四川大学华西医院接受手术的垂体腺瘤患者,分析磁共振成像扫描与内分泌检查所识别的肿瘤复发或残余再生长及相关临床与病理特征。
  • 研究提出并应用了一种新的临床病理分级。

主要发现

  • 中位随访44.0个月后,肿瘤复发见于48例(25.0%),残余进展见于29例(37.2%)。
  • 术后早期复发/进展的危险因素包括:增殖潜能(HR 2.188;P=0.002)、侵袭性(HR 1.698;P=0.029)、较大肿瘤体积(HR 1.029;P=0.004)、高危垂体腺瘤亚型(HR 2.151;P=0.004)、术后残余(HR 1.941;P=0.007)。
  • 就临床病理分级而言,与1a级肿瘤相比,1b级、2a级和2b级腺瘤预后更差,肿瘤复发/进展概率分别增加5.133倍、4.467倍和20.1倍。

关键数值与推荐

  • 增殖潜能:HR 2.188;P=0.002。
  • 侵袭性:HR 1.698;P=0.029。
  • 较大肿瘤体积:HR 1.029;P=0.004。
  • 高危垂体腺瘤亚型:HR 2.151;P=0.004。
  • 术后残余:HR 1.941;P=0.007。

临床怎么用

  • 作者认为该预后分级可能有助于识别侵袭性垂体腺瘤并为患者决定合适的治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Tumor recurrence or residual regrowth are poor prognoses for pituitary adenoma (PA). However, there is no validated and well-accepted prognostic classification of PAs to predict the clinical outcome and guide clinical practice. We analyzed the relevant data of a large cohort of patients with PA and thereafter proposed a new clinicopathologic classification for prognostic prediction. METHODS: Tumor recurrence or residual regrowth identified by magnetic resonance imaging scans and endocrine studies were analyzed along with associated clinical and pathological characteristics for patients who underwent surgery in 2008-2016 at West China Hospital. A new clinicopathologic classification was proposed and applied. RESULTS: After a median follow-up of 44.0 months, tumor recurrence and residual progression were identified in 48 (25.0%) and 29 (37.2%) patients, respectively. Proliferative potential (hazard ratio [HR], 2.188; P = 0.002), invasiveness (HR, 1.698; P = 0.029), larger tumor size (HR, 1.029; P = 0.004), high-risk PA subtype (HR, 2.151; P = 0.004), and postoperative residual (HR, 1.941; P = 0.007) were risk factors for recurrence/progression in the early stage after surgery. With respect to clinicopathologic classification, compared with grade 1a tumors, grade 1b, 2a, and 2b adenomas had poorer prognosis with an increased probability of tumor recurrence/progression of 5.133-fold, 4.467-fold, and 20.1-fold, respectively. CONCLUSIONS: The proposed clinicopathologic classification of PAs showed significant value in predicting prognosis and succeeded in identifying cases with more clinically aggressive lesions with recurrence or residual regrowth. This prognostic classification may be helpful when identifying aggressive PAs and deciding the appropriate therapeutic strategy for patients with PAs.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Lv L, Yin S, Zhou P, et al. Clinical and Pathologic Characteristics Predicted the Postoperative Recurrence and Progression of Pituitary Adenoma: A Retrospective Study with 10 Years Follow-Up. World Neurosurg. 2018. PMID: 29981466. doi:10.1016/j.wneu.2018.06.210

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。